Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enriched CBD oil for methamphetamine use disorder
ACTRN12620000847910Phase 2Not yet recruiting
- Sponsor
- Medical Cannabis Research Australia
- Start
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cannabidiol in methamphetamine use disorder (MUD) (2 arms), sponsored by Medical Cannabis Research Australia. Primary endpoints: Safety assessed by Monitoring of Side Effects Scale at week 12, Relapse assessed by Alcohol, Smoking and Substance Involvement Screening Test at week 12 and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on ACTRN12620000847910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12620000847910.